Safety Study of Chimeric Natriuretic Peptide(CD-NP) in Stable LVAD Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
The most promising chimeric natriuretic peptide designed and studied by our group has been CD-NP which has anti-fibrotic and cardioprotective properties in vivo, vitro and in normal volunteers and human heart failure patients. Since left ventricular assist device (LVAD) can not reverse remodeling of the heart whereas it can improve hemodynamics, CD-NP may be novel anti-fibrotic and anti-remodeling drug as co-therapy during LVAD support.
Epistemonikos ID: 4a3e66f3f7e55466c1b3fe733412e03fa9f00a86
First added on: May 11, 2024